Through Technologies

WARF: P98222US

Human Embryonic Stem Cells


James Thomson

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in a purified preparation of pluripotent human embryonic stem cells.
OVERVIEWA UW-Madison researcher has developed a purified preparation of pluripotent human embryonic stem (ES) cells. These cell lines are capable of indefinite proliferation in an undifferentiated state when cultured on a fibroblast feeder layer, and subsequent differentiation to cells derived from all three embryonic germ layers (ectoderm, mesoderm and endoderm), even after prolonged culture. The human ES cell lines are characterized by the following cell surface markers: SSEA-1 (-), SSEA-4 (+), TRA-1-60 (+), TRA-1-81 (+) and alkaline phosphatase (+). Methods for isolating human ES cells are also provided.
  • Drug discovery
  • Tissue transplantation
  • Disease research
  • Capable of prolonged (greater than one year) proliferation in an undifferentiated state
  • Can differentiate into any cell, including bone, cartilage, muscle, neural and hematopoetic cells, derived from the three embryonic germ layers 
  • Maintain a normal karyotype (e.g., remain euploid) during long-term culture
  • Retain ability to form trophoblast and express chorionic gonadotropin 
  • May be induced to differentiate to specific cell types for tissue transplants to treat diseases such as Parkinson’s (dopanergic neurons), juvenile onset diabetes (pancreatic beta-islet cells) and AIDS (lymphocytes)
The WARF Advantage

Since its founding in 1925 as the patenting and licensing organization for the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.